Haizhou innovative drug exports hit a new high, totaling over $34.3 billion
Innovative drug exports from Haizhou are rising to a record level, indicating increased outbound supply of pharmaceutical products.
Source →The trace
How it reaches your house.
Starting from Hybio Pharmaceutical Co., Ltd, we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.
First impact
Hainan Poly Pharm Co., Ltd. →Prices rise10-Deacetylbaccatin III (10-DAB)
Record export growth at Hainan Poly Pharm likely lifts production demand for 10-DAB, and the 18% dependency with low substitutability and an 18-month replacement lead time makes a meaningful cost squeeze plausible.
76% confidenceHaoshu International (Hao Shu Biotech) →Prices riseCamptothecin (botanical extract)
Rising exports imply higher production at the company, which should lift demand for camptothecin; with 30% market share, low substitutability, and a 60-month replacement lead time, procurement costs are likely to rise.
56% confidenceZhejiang Medicine Co., Ltd. →Prices riseHop 2
Pharmaceutical Key Starting Materials (KSMs) →Stands to benefitChina's 60% KSM supply share makes it the dominant beneficiary if regional innovative-drug export growth lifts KSM demand.
70% confidenceCamptothecin (botanical extract) →supply upCamptothecin is a critical input to cancer and specialty drugs, so higher supply increases downstream drug availability.
69% confidenceCamptothecin (botanical extract) →supply upHaoshu International (Hao Shu Biotech)
Camptothecin availability directly improves a 30% share dependency at Haoshu International, where substitution is limited and replacement lead time is 60 months.
Hop 3
Cancer and specialty drugs →Prices riseCamptothecin (botanical extract)
Higher output of cancer and specialty drugs raises demand for this directly upstream botanical extract, tightening supply and pushing up input costs.
84% confidenceCancer and specialty drugs →Prices riseType I borosilicate glass vials
Greater oncology drug export volume increases packaging demand, which can lift prices for critical sterile vials.
76% confidenceCancer and specialty drugs →Prices riseHop 4
Sterile filtration membrane (0.2 μm) →Stands to benefitMerck KGaA Life Science (MilliporeSigma)MRK.DE
As a roughly 35% share supplier of this sterile filtration membrane, Merck's life-science unit should see stronger demand as drug export volumes lift biomanufacturing output.
82% confidenceSterile filtration membrane (0.2 μm) →Stands to benefitPall has about 30% share of supply for this membrane, so higher production of specialty drugs should increase orders for its filtration products.
80% confidenceSterile filtration membrane (0.2 μm) →Stands to benefit
Where it lands
What you buy, and what you own.
Goods you buy
Cancer and specialty drugs
Companies you may own
Haoshu International (Hao Shu Biotech)600636.SSCSPC Pharmaceutical Group LimitedShanxi Fenge Pharmaceutical Co., Ltd.Divi's Laboratories LimitedSMMTMRK.DEPall Corporation (Danaher)TMOSRT.DEDHRSRTX.DEStevanato Group S.p.A.GXI.DE8086.T
Tap a company to see what it told the SEC could break it.
In the MyPRIA app, this is checked against your own holdings.